ES2084146T3 - Metodo para preparar lineas de celulas b humanas dependientes de factor. - Google Patents

Metodo para preparar lineas de celulas b humanas dependientes de factor.

Info

Publication number
ES2084146T3
ES2084146T3 ES91900209T ES91900209T ES2084146T3 ES 2084146 T3 ES2084146 T3 ES 2084146T3 ES 91900209 T ES91900209 T ES 91900209T ES 91900209 T ES91900209 T ES 91900209T ES 2084146 T3 ES2084146 T3 ES 2084146T3
Authority
ES
Spain
Prior art keywords
cell lines
factor dependent
dependent human
dependent
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91900209T
Other languages
English (en)
Inventor
Jacques Banchereau
Francoise Rousset
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schering Plough Corp
Original Assignee
Schering Plough Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Plough Corp filed Critical Schering Plough Corp
Application granted granted Critical
Publication of ES2084146T3 publication Critical patent/ES2084146T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of El Displays (AREA)
  • Photosensitive Polymer And Photoresist Processing (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
  • Curing Cements, Concrete, And Artificial Stone (AREA)
  • Silicon Polymers (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Light Receiving Elements (AREA)

Abstract

METODO DE FABRICACION DE LINEAS DE CELULAS B HUMANAS FACTOR-DEPENDIENTES. SE FACILITA UN METODO PARA ESTABLECER LINEAS DE CELULAS B HUMANAS FACTOR-DEPENDIENTES CAPACES DE SECRETAR INMUNOGLOBULINA DE UNA ESPECIFICIDAD DESEADA Y CAPAZ DE CULTIVOS A LARGO PLAZO. EL METODO INCLUYE LA SELECCION DE UNA CELULA B QUE TENGA INMUNOGLOBULINA DE LA ESPECIFICIDAD DESEADA Y SU CULTIVO EN PRESENCIA DE UN AGENTE CAPAZ DE DEGRADAR SUS ANTIGENOS SUPERFICIALES CD40. EL CULTIVO A LARGO PLAZO REQUIERE LA PRESENCIA CONTINUA DEL AGENTE DE DEGRADACION. PREFERIBLEMENTE, EL AGENTE DE DEGRADACION ES UN ANTICUERPO MONOCLONAL ESPECIFICO PARA EL ANTIGENO CD40, PRESENTADO POR CELULAS DE MAMIFEROS NO REPLICANTES QUE SE EXPRESAN FCGAMMA-RII.
ES91900209T 1989-12-14 1990-12-13 Metodo para preparar lineas de celulas b humanas dependientes de factor. Expired - Lifetime ES2084146T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19890403491 EP0434879A1 (en) 1989-12-14 1989-12-14 Method of making factor dependent human B cell lines

Publications (1)

Publication Number Publication Date
ES2084146T3 true ES2084146T3 (es) 1996-05-01

Family

ID=8203014

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91900209T Expired - Lifetime ES2084146T3 (es) 1989-12-14 1990-12-13 Metodo para preparar lineas de celulas b humanas dependientes de factor.

Country Status (16)

Country Link
EP (2) EP0434879A1 (es)
JP (1) JPH0789910B2 (es)
AT (1) ATE135041T1 (es)
AU (1) AU655759B2 (es)
CA (1) CA2071886A1 (es)
DE (1) DE69025772T2 (es)
ES (1) ES2084146T3 (es)
FI (1) FI922655A0 (es)
IE (1) IE904498A1 (es)
IL (1) IL96639A0 (es)
MY (1) MY106561A (es)
NO (1) NO922332D0 (es)
NZ (1) NZ236425A (es)
OA (1) OA09701A (es)
WO (1) WO1991009115A1 (es)
ZA (1) ZA909778B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
WO1994004570A1 (en) * 1992-08-21 1994-03-03 Schering Corporation Cd40 ligand, anti cd40 antibodies, and soluble cd40
EP0619323A1 (en) * 1993-04-09 1994-10-12 Schering-Plough Human monoclonal antibodies and processes and materials for making such antibodies
US5959085A (en) * 1993-11-23 1999-09-28 Schering Corporation Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
EP0659766A1 (en) * 1993-11-23 1995-06-28 Schering-Plough Human monoclonal antibodies against human cytokines and methods of making and using such antibodies
DK0763057T3 (da) 1994-04-28 2006-03-27 Boehringer Ingelheim Pharma Fremgangsmåde til proliferering og differentiering af B celler og anvendelse deraf
US6465251B1 (en) * 1996-11-13 2002-10-15 Dana-Farber Cancer Institute, Inc. Method of promoting b-cell proliferation and activation with CD40 ligand and cyclosporin
EP1033406A4 (en) * 1997-10-27 2005-03-09 Sumitomo Electric Industries INDUCER FOR THE PRODUCTION OF ANTIGEN-SPECIFIC ANTIBODY, EXPRESSION VECTOR CONTAINING THE GENE REQUIRED THEREFOR, AND METHOD FOR INDUCING THE PRODUCTION OF THE ANTIGEN-SPECIFIC ANTIBODY
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2002028905A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Human anti-cd40 antibodies
EP2011802A3 (en) 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
GB2398783A (en) 2003-02-26 2004-09-01 Antonio Lanzavecchia A method for producing immortalised human B memory lymphocytes
AU2004215125B2 (en) 2003-02-26 2011-01-06 Institute For Research In Biomedicine Monoclonal antibody production by EBV transformation of B cells
CN101253409A (zh) 2005-08-02 2008-08-27 埃克斯生物科技公司 使用IL-1α自身抗体诊断、治疗和预防血管疾病
DK2464664T3 (da) 2009-08-13 2016-01-18 Crucell Holland Bv Antistoffer mod humant respiratorisk syncytialvirus (rsv) og fremgangsmåder til anvendelse deraf
EP2316920A1 (en) 2009-10-30 2011-05-04 BioNTech AG Clonal expansion of B cells
EP2591000B1 (en) 2010-07-09 2017-05-17 Janssen Vaccines & Prevention B.V. Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
WO2013000982A1 (en) 2011-06-27 2013-01-03 Vivalis Method for screening cells

Also Published As

Publication number Publication date
WO1991009115A1 (en) 1991-06-27
FI922655A7 (fi) 1992-06-09
NO922332L (no) 1992-06-12
JPH05503214A (ja) 1993-06-03
IL96639A0 (en) 1991-09-16
JPH0789910B2 (ja) 1995-10-04
FI922655A0 (fi) 1992-06-09
CA2071886A1 (en) 1991-06-15
DE69025772D1 (de) 1996-04-11
EP0434879A1 (en) 1991-07-03
EP0505397B1 (en) 1996-03-06
MY106561A (en) 1995-06-30
AU655759B2 (en) 1995-01-12
AU6901791A (en) 1991-07-18
IE904498A1 (en) 1991-06-19
EP0505397A1 (en) 1992-09-30
DE69025772T2 (de) 1997-02-06
ZA909778B (en) 1991-10-30
OA09701A (en) 1993-08-30
ATE135041T1 (de) 1996-03-15
NO922332D0 (no) 1992-06-12
NZ236425A (en) 1993-02-25

Similar Documents

Publication Publication Date Title
MY106561A (en) Method of making factor-dependent human b cell lines
DE3580654D1 (de) Menschlicher hybridomfusionspartner zur herstellung menschlicher monoklonaler antikoerper.
AU567693B2 (en) Human monoclonal antibodies against bacterial toxins
JPS5695123A (en) Hybrid cell line* antibody and method for manufacturing monoclonal antibody to human prothymocyte cell
GB2000186A (en) Method of producing antibodies in vitro
YU45871B (sh) Polipeptid sa humanim imunointerferonskim (ifn-gama) svojstvima
ES2109228T3 (es) Anticuerpos monoclonales mejorados contra el receptor de las celulas t alfa/beta humano, su produccion y uso.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
EP0967277A3 (en) Production of chimeric mouse-human antibodies with specificity to human tumor antigens
NO803660L (no) Hybridcellelinje for fremstilling av monoklonalt antistoff til et antigen.
ATE15693T1 (de) Zellkultur-verfahren.
EP0396505A3 (en) Monoclonal antibodies specific for an immunoglobulin isotype
JPS53127750A (en) Optical distrubutor
DE3585049D1 (de) Monoklonale antikoerper.
IT7922818A0 (it) Procedimento per mantenere attiva la cultura di fermenti.
EP0404003A3 (en) Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
ES8707296A1 (es) Un metodo para producir anticuerpos monoclonales humanos
EP0166458A3 (en) Monoclonal antibody capable of specifically distinguishing human hepato-carcinoma cells
IT7924358A0 (it) Antibiotici, procedimento per laloro preparazione, e coltura biologicamente pura per impiego in tale procedimento.
JPS55156588A (en) Method for culturing photosynthetic bacteria, and covering material using therefor
SU1398393A1 (ru) Штамм гибридных культивируемых клеток животных mus musculus, используемый для получения моноклональных антител к микобактериям туберкулеза
ATA540475A (de) Fermenter zur zuchtung von mikroorganismen, insbesondere von backhefe
IT7821522A0 (it) Procedimento per favorire la crescita di microorganismi fotosintetici e organismi simili.
SU1529724A1 (ru) Штамм культивируемых гибридных клеток животного mus musculus - продуцент моноклонального антитела к термостабильному поверхностному антигену возбудителя сапа
HRP940786B1 (en) Hybrid cell line for production of monoclonal antibody for human cytotoxic and supressor t cells, antibody and process

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 505397

Country of ref document: ES